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Abstract 738: Increased Ret signalling and impact of vandetanib in acquired tamoxifen resistant breast cancer 
Julia M. Gee, Lindy Goddard, Huw J. Mottram, Rajpal S. Burmi, Sara L. Pumford, Carol 
M. Dutkowski, Denise Barrow, Iain R. Hutcheson, Robert I. Nicholson, Ian O. Ellis and Paul Elvin 
 
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA 
Abstract 
Deregulation of the tyrosine kinase Ret and its coreceptors ;GFRαͿ has ďeeŶ iŵpliĐated iŶ Ŷeoplasia, aŶd Ret 
is of interest as a therapeutic target in endocrine-treated breast cancer. This study evaluated in vitro impact 
of vandetanib, a tyrosine kinase inhibitor able to target Ret in addition to EGFR and VEGFR2, in ER+ breast 
cancer cells that have acquired resistance to tamoxifen treatment. 
Tamoxifen resistant TAMR and endocrine responsive MCF7 cells were grown in vitro for 7 days +/- 
vandetanib (0.5-ϱμMͿ +/- exogenous growth factors (10-50ng/ml), and also in continuous culture with 
ǀaŶdetaŶiď ;ϭμMͿ, to ŵoŶitor groǁth iŵpaĐt aŶd eŵergeŶĐe of ǀaŶdetaŶiď resistaŶĐe. For WesterŶ ďlottiŶg 
or immunoprecipitation, log phase cells were transferred for 24hr to serum-free medium and pre-treated 
for 1hr +/- vandetanib followed by Ret ligands GDNF or artemin for 5mins. Immunohistochemistry for Ret 
activity was performed on an ER+ tamoxifen-treated clinical breast cancer TMA sample series using Y1062 
Ret phospho-antibody with HScore staining assessment. 
Growth of TAMR cells was suďstaŶtiallǇ iŶhiďited ďǇ ǀaŶdetaŶiď ;p<Ϭ.ϬϬϭ, ICϱϬ Ϭ.ϲμMͿ ǁith Đoŵplete Đell 
loss by 17weeks, contrasting rapid emergence of resistance in endocrine responsive MCF7 cells. TAMR cells 
ǁere ŵore seŶsitiǀe to ǀaŶdetaŶiď ǀs. gefitiŶiď ;p<Ϭ.ϬϬϭ; ϭμM eaĐh agent), indicating mitogenic signalling 
in addition to EGFR contributed to TAMR growth. TAMR cells had elevated basal Ret expression, activity and 
iŶteraĐtioŶ ǁith eleǀated GFRαϯ ĐoreĐeptor eǆpressioŶ; ŵature VEGFRϮ ǁas Ŷot deteĐted iŶ TAMR Đells. 
Exogenous GFRαϯ ligaŶds arteŵiŶ or GDNF ŵodestlǇ stiŵulated TAMR Đell groǁth aŶd hǇperaĐtiǀated Ret, 
doǁŶstreaŵ kiŶases ;iŶĐludiŶg MAPK, AKTͿ aŶd ER Serϭϲϳ, ĐoŶfirŵiŶg fuŶĐtioŶal GFRα/Ret sigŶalliŶg aŶd its 
cross-talk with ER. Increased phospho-Ret immunostaining was also associated with shortened DFI (p=0.036) 
and survival (p=0.011) in tamoxifen-treated clinical ER+ breast cancers. Vandetanib (0.5-ϭμMͿ depleted 
GFRαϯ/Ret aĐtiǀitǇ aŶd deĐreased phospho-EGFR in TAMR cells under basal and Ret ligand-stimulated 
conditions, inhibited MAPK, p70S6K and S6RP phosphorylation, and partially-reduced levels of phospho-AKT 
and phospho-ER. However, vandetanib failed to consistently impact on HER2, 3 or 4 activity; moreover, 
hyperactivation of all erbB receptors by exogenous heregulin B1 (10ng/ml) recovered AKT, MAPK, p70S6K 
and ER AF-1 phosphorylation in the presence of vandetanib and was able to overcome the basal growth-
inhibitory impact of this agent in TAMR cells. 
These findings demonstrate a central importance for increased Ret signalling and its cross-talk with ER in 
tamoxifen resistant breast cancer that can be targeted in vitro by vandetanib. Further studies are required 
to determine optimal combination treatments with vandetanib to circumvent potential intrinsic resistance 
in clinical breast cancers that exhibit heregulin B1 enrichment. 
 
